ArticleJGH open : an open access journal of gastroenterology and hepatology2025
Compounding Prevalence of Inflammatory Bowel Disease in a 2024 Population-Based Study From Canterbury, New Zealand.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between different drinks consumption and risk of inflammatory bowel disease: a dose-response meta-analysis.Frontiers in nutrition · 2026Pooled it
- Dietary Patterns and Food Choices of Adults With Inflammatory Bowel Disease in New Zealand.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Inflammatory bowel disease phenotypes in diverse populations: a global comparative analysis.Journal of Crohn's & colitis · 2026Article
- Effects of exercise therapy on quality of life in patients with inflammatory bowel disease: a network meta-analysis.Frontiers in physiology · 2026Article
- Introducing a foundational sequence transformer for range adaptive nucleotide decoding (STRAND).Briefings in bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: The epidemiological patterns of inflammatory bowel disease (IBD) can give insights into disease etiology and health system burden. This study aimed to measure the population-based prevalence in Canterbury and consider the region's position within the 4-stage epidemiological model of IBD. Methods: Gastroenterology clinics in Canterbury were searched for patients with a confirmed diagnosis of IBD. Demographic and disease details (including Montreal phenotype) were extracted from individual medical records. The prevalence of IBD, Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU) was established for the total population and for age, sex, and ethnic sub-groups. Results: Altogether 4042 individuals (1 in 150 people) in Canterbury with IBD were identified. The point prevalence of IBD on 1st January 2024 was 671 (95% CI 651-692) per 100 000 persons. The prevalence of CD 386 (95% CI 370-402) was higher than UC 264 (95% CI 251-277) each per 100 000. Almost three times as many individuals had IBD in 2024, compared to a 2005 study. The majority of the cohort were New Zealand European (92.9%) followed by Māori (4.2%), Asian (2.6%) and Pacific peoples (0.3%). Older adults (65+ years) comprised 21% of the population with a prevalence of 845 (95% CI 789-904) per 100 000 persons. Conclusion: Canterbury has the highest reported prevalence of IBD in Oceania to date, and there is a growing proportion of older age patients. The rapid rise in cases supports the hypothesis that Canterbury is in the compounding prevalence stage of the epidemiological model of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.